Urology

Spedra^®

Spedra^® is indicated for the treatment of erectile dysfunction (ED) in adult men.¹

Spedra^® (avanafil) differs from other phosphodiesterase-5 (PDE-5) inhibitors in that it has a unique molecular structure² that enables a particularly rapid onset of action and a long duration of action combined with good tolerability. Through these properties, Spedra^® helps affected men regain their sexual spontaneity.^1-6 The good tolerability of Spedra^® is due to the high selectivity of the active ingredient on PDE-5^2,3 and has been proven in comprehensive clinical studies.^3-5 Sexual stimulation is required for Spedra to be effective.¹

References: 1 Drug information Spedra® 2 Kedia GT et al. Ther Adv Urol 2013; 5: 35-41,3 Goldstein I et al. J Sexual Med 2012; 9: 1122-33, 4 Goldstein I et al. Mayo Clin Proc 2012; 87(9): 843-52, 5 Mulhall JP et al. J Urol 2013; 189: 2229-36,6 Wang R et al. J Sex Med 2012; 9:2122-9

Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain a penile erection for satisfactory sexual intercourse.¹ The etiology of ED can be organic, psychogenic, or mixed.¹ ED is often indicative of an underlying and previously unrecognized comorbid condition, such as cardiovascular disease or diabetes. For example, studies show that depending on the severity of ED, men are at increasing risk for developing coronary artery disease (CAD), as well as cardiovascular events (e.g., myocardial infarction).^2,3 ED can also develop after penile injury, surgery, or as a result of drug side effects. Psychogenic factors for ED include anxiety, depression, or relationship problems.¹ ED can occur at any age; however, the proportion of men with ED remains stable (about 25%) until age 50 and only increases thereafter. Austrian data put the prevalence at 37.5% between the ages of 51 and 60 and as high as 71.2% between the ages of 71 and 80.⁴

References: 1 Salonia et al, Eur Urol. 2021;80(3):333-357, 2 Ponholzer et al, Eur Urol 2005;48:512–8,3 Ponholzer et al, Int J Impot Res. 2010;22(1):25-9, 4 Ponholzer et al, Eur Urol 2005;47:80-6.

AT-WEB-26-10-2021